GET DAILY SIGNALSVerastem Oncology (VSTM): A -11.4% Monthly Pullback Amid Pipeline Progress
Key Takeaways
- Verastem Oncology shares declined roughly 11.4% over the last 30 days, from $9.23 on October 15, 2026, to $8.18 as of the most recent close.
- The pullback followed third-quarter 2026 results that missed consensus estimates and a more cautious near-term outlook for the AVMAPKI/FAKZYNJA CO-PACK commercial launch.
- Despite the recent slide, the stock remains up about 24% over the trailing three-month period, supported by encouraging VS-7375 data and a strengthened balance sheet.
- VS-7375, Verastem's oral KRAS G12D (ON/OFF) inhibitor, delivered early efficacy signals across pancreatic, lung, and colorectal cancers and cleared the path toward a planned Phase 3 program.
- A $250 million October financing lifted pro forma cash to about $422.8 million, extending the company's projected operating runway into the first half of 2028.
- For additional context, explore Verastem Oncology's Price Targets, Earnings, and Forecast pages.
- To monitor automated trading signals for this and other names, explore Trending AI Robots.
Company Snapshot: Verastem Oncology (VSTM) Focus and Position
Verastem Oncology is a biopharmaceutical company focused on developing and commercializing therapies for cancers driven by RAS pathway mutations. Its lead commercial product is the AVMAPKI (avutometinib) and FAKZYNJA (defactinib) combination, marketed as the CO-PACK, which is approved for the treatment of KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). The company's pipeline is anchored by VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor being developed for pancreatic, colorectal, and non-small cell lung cancers.
Verastem operates at the intersection of a rare-disease commercial franchise and a clinical-stage oncology pipeline. Investors follow the stock for two primary reasons: the trajectory of the CO-PACK launch in a small but underserved patient population, and the broader potential of VS-7375 to address one of the most common and historically difficult-to-drug oncogenic mutations. Competitive strengths include a differentiated dual ON/OFF inhibitor design intended to improve efficacy and tolerability relative to pan-RAS approaches. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
VSTM Stock Performance: The Last 30 Days Versus the Quarter
Over the last 30 days, VSTM shares fell approximately 11.4%, declining from a closing price of $9.23 on October 15 to $8.18 as of the most recent trading session. The move was not a straight line: the stock climbed to an intraday peak above $10 in late October before giving back those gains in early November.
The longer-term picture is more constructive. Over the trailing three-month period, the stock is up roughly 24%, having advanced from about $6.58 in mid-August to its current level. This reflects a sharp October re-rating tied to clinical data and a capital raise, followed by a partial retracement as investors digested a softer commercial update and widening losses.
Drivers Behind the Recent 30-Day Decline
The primary catalyst for the recent decline was Verastem's third-quarter 2026 earnings report. The company posted net product revenue of $24.0 million, an increase of 114% year over year, but the figure fell short of consensus estimates, and CO-PACK revenue declined sequentially from $25.1 million in the second quarter. The non-GAAP adjusted net loss widened to $72.8 million, or $0.72 per share, from $39.1 million, or $0.53 per share, a year earlier, as research and development spending accelerated.
Management signaled a "more gradual" commercial ramp for the CO-PACK, citing moderation in new patient starts, seasonal headwinds, and the episodic nature of treatment persistence in a rare-disease market. This tempered near-term revenue expectations and contributed to the post-earnings selloff. The pullback also reflected broader profit-taking after the stock's sharp October run-up, even as several analysts maintained Buy ratings on the name.
What Supported the Three-Month Advance
The three-month advance was driven largely by Verastem's VS-7375 program. In October, the company reported first U.S. clinical data showing a confirmed response rate of 41% in second-line-plus pancreatic cancer, with a higher rate in the second-line setting, a 67% six-month progression-free survival rate, and two complete responses. Additional signals in lung and colorectal cancers reinforced enthusiasm for the KRAS G12D opportunity.
Verastem also reached alignment with the FDA on the design of TARGET-D 301, a Phase 3 trial in first-line KRAS G12D-driven metastatic pancreatic cancer, and completed a roughly $250 million follow-on equity offering that strengthened its balance sheet. These developments, combined with priority review for a new CO-PACK tablet and blister-pack presentation, supported the stock's re-rating earlier in the quarter.
Key Catalysts to Watch for VSTM
Investors monitoring Verastem should watch several upcoming catalysts. On the clinical side, the company plans to open TARGET-D 301, its Phase 3 trial in first-line pancreatic cancer, before the end of 2026, with additional Phase 3 programs in colorectal and lung cancers targeted for the first half of 2027. Data readouts from the ongoing Phase 2 VS-7375 studies and further regulatory engagement will be closely followed.
On the commercial side, the FDA has granted priority review to the new AVMAPKI tablet and blister-pack presentation, with a decision expected by early February 2027. Investors will also track whether CO-PACK revenue resumes sequential growth and whether new patient starts stabilize. A planned CEO transition at the start of 2027 introduces an additional execution variable, while rising research and development spending remains a key factor in the company's path toward a larger commercial business.
AI Tools in Portfolio Monitoring
In my own workflow, I often turn to Tickeron’s AI Trading Bots to observe how algorithmic strategies are positioned around names like this one. The platform offers a range of bots with different timeframes and approaches, which can provide an additional layer of perspective when evaluating volatile biotech names alongside traditional analysis. AI Trading Bots
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
VSTM in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 06, 2026
VSTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 36 cases where VSTM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where VSTM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where VSTM advanced for three days, in 204 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VSTM as a result. In 73 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for VSTM turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
VSTM moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. VSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.237) is normal, around the industry mean (3.498). P/E Ratio (-3.447) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that discovers and develops drugs
Industry Biotechnology
Advertisement